Given the interrelationship among inflammation, metabolic syndrome, and diabetes, it is not surprising that antihyperglycemic agents such as metformin and thiazolidinedione have been shown to lower hsCRP levels. In a 26-wk trial among patients with type 2 diabetes, rosiglitazone therapy reduced hsCRP levels and other inflammatory markers (118). Changes in hsCRP level were uncorrelated with changes in glycemic control, as measured by hemoglobin A1c (r = 0.06) and fasting glucose level (r = 0.06) and were only minimally correlated with changes in insulin resistance (r = 0.13). Whether the ability of such agents to lower hsCRP has clinical relevance beyond improvements in glycemic control is a focus of current research.
Was this article helpful?